Transatlantic Active Surveillance on Cardiovascular Safety of NuvaRing (TASC) (TASC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00524771

Recruitment Status : Completed

First Posted : September 5, 2007

Results First Posted : April 9, 2014

Last Update Posted : April 9, 2014

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborator:

Organon

Information provided by (Responsible Party):

Juergen Dinger, MD, PhD, Center for Epidemiology and Health Research, Germany

Study Description

Brief Summary:

The objective of this study is to characterize and compare the risks of short- and long-term use of NuvaRing® with marketed combined oral contraceptives.

Condition or disease
Contraception

Show detailed description

Detailed Description:

This is a large, multinational, controlled, prospective, active surveillance study of women who are prescribed NuvaRing® or an oral contraceptive (OC). The study follows two cohorts. The cohorts consist of new users (starters and switchers) of two different groups of hormonal contraceptives:

NuvaRing®
marketed combined OCs (combined oral contraceptives)

NuvaRing® is a transparent and flexible contraceptive vaginal ring containing etonogestrel and ethinylestradiol (EE). The ring releases 15 mcg EE and 120 mcg etonogestrel daily. After insertion it remains in the upper part of the vagina for 21 days, followed by 7 ring-free days before a new ring is inserted.

The primary objective of this study is to characterize and compare the risks of short- and long-term use of NuvaRing® with marketed combined OCs. The main clinical outcomes of interest for the short and long-term follow-up are:

Deep Venous Thrombosis (DVT)
Pulmonary Embolism (PE)
Acute Myocardial Infarction (AMI)
Cerebrovascular Accidents (CVA)

Secondary objectives are:

to analyze the drug utilization pattern of NuvaRing® and marketed OCs in a study population that is representative for typical use of the individual contraceptive methods under routine medical conditions
to characterize the baseline risk of users of the individual formulations
to assess the compliance of NuvaRing® users and users of marketed OCs
to analyze the reasons for discontinuing the treatment with NuvaRing® and/or marketed OCs.

The study will use a non-interference approach to provide standardized, comprehensive, reliable information on these treatments in a routine clinical practice setting.

Study participants will be recruited via an international network of more than 1000 gynecologists. After study entry cohort members will be followed for a period of 30 to 48 months for rare serious safety outcomes. Regular, active contacts with the cohort members by the study team of the Berlin Center for Epidemiology and Health Research (ZEG), Germany will provide the necessary information on health-related events or changes in health status (= active surveillance).

Approximately 15,000 subjects per cohort will be recruited by participating physicians in order to provide approx. 86,000 women-years (WY) of observation. Subjects will be considered for enrollment in this study after the participating physician has determined that NuvaRing® or OC use is appropriate. There will be no specific inclusion/exclusion criteria. All women who are eligible are to be asked by their physician if they are willing to participate. As this a non-interventional study, the possibility to participate in the study should not be discussed with the patient before both - physician and patient - agree upon the prescription.

The study will be conducted in several European countries and the United States.

The study will be divided into 2 phases: a baseline survey which includes an initial consultation at baseline with a participating physician, and a follow-up phase which includes two follow-up contacts within the first year and then annual follow-up contacts for up to 4 years post-baseline.

The study will maintain scientific independence and will be governed by an independent Safety Monitoring and Advisory Council (SMAC). The Berlin Center for Epidemiology and Health Research (ZEG) and its research team will be accountable to the council in all scientific matters. The members of the council will be international experts in relevant scientific fields (e. g., epidemiology, drug safety, gynecology, cardiology, statistics, endocrinology).

Study Design

Layout table for study information

Study Type :	Observational
Actual Enrollment :	34100 participants
Observational Model:	Cohort
Time Perspective:	Prospective
Official Title:	Transatlantic Active Surveillance on Cardiovascular Safety of NuvaRing (TASC)
Study Start Date :	September 2007
Actual Primary Completion Date :	March 2012
Actual Study Completion Date :	June 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Birth Control

U.S. FDA Resources

Groups and Cohorts

Group/Cohort
1 Users of NuvaRing
2 Users of combined oral contraceptives

Outcome Measures

Primary Outcome Measures :

Number of Participants With Venous Thromboembolism (VTE) [ Time Frame: Time to event analysis within 48 months ]
Venous thromboembolism (VTE) associated with the use of hormonal contraceptives that contain both an estrogen and progestin.
Number of Participants With Arterial Thromboembolism (ATE) [ Time Frame: Time to event analysis within 48 months ]
Arterial Thromboembolism (ATE) associated with the use of hormonal contraceptives that contain both an estrogen and progestin.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	Child, Adult, Older Adult
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

Women prescribed hormonal contraceptives by gynecologists

Criteria

Inclusion Criteria:

women who are prescribed NuvaRing® or a combined oral contraceptive and who are new users (Starters, restarters or switchers) of the formulation

Exclusion Criteria:

women who do not consent to participate in the study

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00524771

Locations

Layout table for location information

Germany
Berlin Center for Epidemiology and Health Research
Berlin, Germany, 10115

Sponsors and Collaborators

Center for Epidemiology and Health Research, Germany

Organon

Investigators

Layout table for investigator information

Principal Investigator:	Juergen C Dinger, MD, PhD	Center for Epidemiology and Health Research Berlin, Germany

More Information

Publications of Results:

Dinger J, Mohner S, Heinemann K. Cardiovascular risk associated with the use of an etonogestrel-containing vaginal ring. Obstet Gynecol. 2013 Oct;122(4):800-808. doi: 10.1097/AOG.0b013e3182a5ec6b.

Layout table for additonal information

Responsible Party:	Juergen Dinger, MD, PhD, Principal Investigator, Center for Epidemiology and Health Research, Germany
ClinicalTrials.gov Identifier:	NCT00524771
Other Study ID Numbers:	ZEG2007_03
First Posted:	September 5, 2007 Key Record Dates
Results First Posted:	April 9, 2014
Last Update Posted:	April 9, 2014
Last Verified:	March 2014

Keywords provided by Juergen Dinger, MD, PhD, Center for Epidemiology and Health Research, Germany:


Contraception Contraceptive Vaginal Ring

To Top